Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Corcept Therapeutics (CORT) over the last 12 years, with Q2 2025 value amounting to $57000.0.

  • Corcept Therapeutics' Capital Expenditures fell 8629.81% to $57000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $282000.0, marking a year-over-year decrease of 8625.06%. This contributed to the annual value of $2.2 million for FY2024, which is 146258.99% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Capital Expenditures of $57000.0 as of Q2 2025, which was down 8629.81% from $104000.0 recorded in Q1 2025.
  • Over the past 5 years, Corcept Therapeutics' Capital Expenditures peaked at $1.6 million during Q3 2024, and registered a low of $12000.0 during Q1 2022.
  • Over the past 5 years, Corcept Therapeutics' median Capital Expenditures value was $104000.0 (recorded in 2025), while the average stood at $223600.0.
  • Per our database at Business Quant, Corcept Therapeutics' Capital Expenditures crashed by 9047.62% in 2022 and then surged by 431891.89% in 2024.
  • Corcept Therapeutics' Capital Expenditures (Quarter) stood at $65000.0 in 2021, then plummeted by 52.31% to $31000.0 in 2022, then grew by 19.35% to $37000.0 in 2023, then surged by 227.03% to $121000.0 in 2024, then tumbled by 52.89% to $57000.0 in 2025.
  • Its last three reported values are $57000.0 in Q2 2025, $104000.0 for Q1 2025, and $121000.0 during Q4 2024.